Table 1 |
||||
|
Estimated IC50 doses of breast cell lines treated with EGFR, MEK, and PI3K inhibitors |
||||
|
Cell Line |
Gefitinib (μM) |
Cetuximab (μg/mL) |
U0126 (uM) |
LY294002 (uM) |
|
|
||||
|
ME16C |
0.3 (0.02) |
>100a |
19.7 (0.66) |
21.2 (0.63) |
|
HME-CC |
0.2 (0.01) |
>100a |
12.7 (0.33) |
7.3 (0.17) |
|
SUM102 |
0.1 (0.002) |
2.3 (0.15) |
4.3 (0.20) |
3.4 (0.10) |
|
SUM149 |
4.7 (0.14) |
>100a |
21.8 (0.80) |
18.4 (0.48) |
|
MCF-7 |
21.1 (0.29) |
>100a |
17.0 (1.15) |
3.9 (0.13) |
|
ZR-75-1 |
11.1 (0.12) |
>100a |
25.0 (0.74) |
2.4 (0.05) |
|
|
||||
|
72 h IC50 doses were calculated for the EGFR inhibitors gefitinib, cetuximab, the MEK1/2 inhibitor U0126, and the PI3K inhibitor LY294002. Note that the standard errors are presented within () aNo achievable IC50 dose with doses up to 100 μg/mL |
||||
|
Hoadley et al. BMC Genomics 2007 8:258 doi:10.1186/1471-2164-8-258 |
||||
